Explore

AI Integration in Medicare Sparks Legislative Pushback Over Patient Care Concerns

AI Integration in Medicare Sparks Legislative Pushback Over Patient Care Concerns

The Centers for Medicare and Medicaid Services (CMS) introduced the 'Wasteful and Inappropriate Service Reduction' (WISeR) model to enhance Medicare payment efficiency through AI and machine learning. This initiative, set to begin in six states on January 1, aims to reduce waste and fraud by scrutinizing claims. However, it has faced opposition from lawmakers, including Rep. Ami Bera, who argue that healthcare decisions should remain in the hands of doctors, not algorithms. The debate centers on the balance between technological efficiency and maintaining human clinical judgment in patient care.

Digital Transformation in Healthcare: Alfred Olivares Discusses Affordability and Innovation

Digital Transformation in Healthcare: Alfred Olivares Discusses Affordability and Innovation

Digital Transformation in Healthcare: Alfred Olivares Discusses Affordability and Innovation

CLEAR Partners with CMS to Enhance Healthcare Identity Verification

CLEAR Partners with CMS to Enhance Healthcare Identity Verification

CLEAR, a company known for its identity verification technology, has signed a contract with the Centers for Medicare & Medicaid Services (CMS) to improve identity verification in healthcare. This partnership is part of CMS's 'Kill the Clipboard' initiative, aimed at modernizing Medicare by enhancing interoperability and reducing fraud. CLEAR's technology uses biometric data and document checks to confirm identities, and it will be integrated into Medicare services to streamline patient verification processes.

FDA probes deaths likely related to COVID vaccines across age groups

FDA probes deaths likely related to COVID vaccines across age groups

Dec 9 (Reuters) - The U.S. health regulator is investigating deaths potentially related to COVID-19 vaccines across multiple age groups as part of a safety review, a spokesperson for the Department of Health and Human Services said on Tuesday.

Children's Health Defense Petitions FDA to Revoke COVID Vaccine Licenses Amid Safety Concerns

Children's Health Defense Petitions FDA to Revoke COVID Vaccine Licenses Amid Safety Concerns

Children's Health Defense (CHD) has filed a Citizen Petition with the U.S. Food and Drug Administration (FDA) requesting the revocation of licenses for Pfizer-BioNTech and Moderna COVID-19 vaccines. The petition argues that the FDA granted full licensure without adhering to the legal standards typically required for licensed vaccines. CHD CEO Mary Holland claims the FDA violated its own rules under the Biden administration by granting biologics licenses to these vaccines. The petition, supported by research from industry veteran Sasha Latypova, alleges that the vaccines were misbranded and adulterated, having bypassed necessary clinical investigations. CHD is urging the public to submit comments on the petition, emphasizing the need for transparency and integrity at the FDA.

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

NeuroPace, Inc. has announced positive results from the 18-month NAUTILUS trial, which evaluated the RNS System as an adjunctive therapy for drug-resistant idiopathic generalized epilepsy (IGE). The trial showed a 77% median reduction in generalized tonic-clonic seizures, with significant improvements in patient and physician ratings of overall change. These findings support NeuroPace's plan to submit a PMA supplement to the FDA for indication expansion by the end of 2025. The RNS System, a brain-responsive platform, offers a new treatment option for patients with IGE who do not respond to antiseizure medications.

CLEAR Partners with CMS to Enhance Identity Verification in Medicare

CLEAR Partners with CMS to Enhance Identity Verification in Medicare

CLEAR, a company known for its identity verification technology, has announced a new contract with the Centers for Medicare & Medicaid Services (CMS) as part of the CMS Health Tech Ecosystem Initiative. This partnership is a significant step in the CMS's 'Kill the Clipboard' initiative, aimed at modernizing Medicare by improving interoperability and reducing fraud. CLEAR's technology, which uses biometric data and document checks, will be implemented to verify identities across healthcare organizations. This initiative is expected to streamline processes for Medicare beneficiaries and providers, allowing them to create and recover accounts and access healthcare information more securely. The technology is set to roll out on Medicare.gov in early 2026 and is compliant with HIPAA and IAL2 standards, ensuring patient data protection.

AI-Powered Radiology Tools Enhance Early Disease Detection and Population Health

AI-Powered Radiology Tools Enhance Early Disease Detection and Population Health

AI-assisted diagnostics are transforming the landscape of healthcare by improving early disease detection and intervention. A2z Radiology AI's CT triage system has significantly reduced reporting time and mental demand for radiologists. PathAI's AIM-MASH tool, now FDA-qualified, standardizes pathology assessments in clinical trials, addressing data variability. AI tools like LabTest Checker have demonstrated high diagnostic accuracy, particularly in emergencies. These advancements are not about replacing clinicians but supporting them by reducing non-clinical tasks and enhancing diagnostic confidence. The focus is on making preventive care and early detection more accessible, ultimately improving population health.

Castlight and Noom Partner to Address GLP-1 Cost Crisis with Integrated Health Platform

Castlight and Noom Partner to Address GLP-1 Cost Crisis with Integrated Health Platform

Castlight and Noom Partner to Address GLP-1 Cost Crisis with Integrated Health Platform

FDA Qualifies PathAI's AIM-MASH Tool, Revolutionizing MASH Clinical Trials

FDA Qualifies PathAI's AIM-MASH Tool, Revolutionizing MASH Clinical Trials

PathAI has achieved a significant milestone with the FDA qualification of its AIM-MASH AI Assist tool, marking it as the first AI-powered pathology biomarker to receive such status under the FDA's Drug Development Tool program. This follows a similar qualification from the European Medicines Agency, establishing AIM-MASH as the first tool with dual U.S. and EU regulatory recognition. The tool addresses variability in MASH clinical trials by standardizing liver biopsy scoring, thus reducing human variability and enabling more accurate enrollment and endpoint assessment.

PureTech Advances Deupirfenidone for Idiopathic Pulmonary Fibrosis with FDA Support

PureTech Advances Deupirfenidone for Idiopathic Pulmonary Fibrosis with FDA Support

PureTech Health has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its drug candidate deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF). The FDA's feedback supports the advancement of deupirfenidone into a pivotal Phase 3 trial, which is set to begin in the first half of 2026. Deupirfenidone is being developed by Celea Therapeutics, a PureTech Founded Entity, and aims to become a new standard of care for IPF, a progressive and fatal lung disease. The Phase 3 SURPASS-IPF trial will compare deupirfenidone to pirfenidone, an existing FDA-approved therapy, to assess its efficacy and safety.

CMS Relief Funds Misallocated Following Change Healthcare Cyberattack

CMS Relief Funds Misallocated Following Change Healthcare Cyberattack

A University of Minnesota analysis has revealed that the Centers for Medicare & Medicaid Services (CMS) overpaid many hospitals while failing to provide adequate relief to others following the 2024 Change Healthcare cyberattack. The Change Healthcare/Optum Payment Disruption (CHOPD) program, which distributed $3.3 billion in accelerated payments, was intended to support providers whose revenue cycles were disrupted by the cyberattack. However, the study found that at least 312 hospitals with significant revenue disruptions did not receive any funds, while about a third of the hospitals that did receive payments were overcompensated by $1 million or more. The program's opt-in nature and lack of targeted relief for the most affected providers were highlighted as areas needing improvement.